electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology
December 12 2023 - 8:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, today announced the United States
Patent and Trademark Office has issued a patent related to a system
for stimulating a nerve target in the head or neck of a patient for
treatment of various disorders, such as primary headache.
U.S. Patent No. 11,839,764 entitled “Systems and Methods for
Treating a Medical Condition with an Electrical Stimulation
Treatment Regimen” was issued on December 12, 2023, and is
generally related to a system including a downloadable software
program on, for example, a mobile device, that is configured to
control a parameter of the electrical impulses delivered by a
stimulator for targeting nerves in the head or neck of a patient to
treat various disorders such as primary headache, among others.
“We continue to grow our intellectual property portfolio,”
stated Joshua Lev, Chief Strategy Officer of electroCore. “This new
patent strengthens our position around systems that utilize mobile
applications to control stimulators that treat various disorders
such as primary headache, which may be useful as we develop our
next generation application enabled products and devices.”
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans including potential commercial
applications of nVNS and treatment paradigms; its pipeline or
potential markets for its technologies including systems related to
stimulating nerve targets at the head of a patient for treatment of
various disorders; the timing, outcome and impact of regulatory,
clinical and commercial developments; the issuance of U.S. and
international patents, including patents related to non-invasive
nerve stimulation with mobile devices, providing expanded IP
coverage; the possibility of future business models, the potential
of nVNS generally and gammaCore in particular and other statements
that are not historical in nature, particularly those that utilize
terminology such as "anticipates," "expects," "believes,"
"intends," other words of similar meaning, derivations of such
words and the use of future dates. Actual results could differ from
those projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to obtain
additional financing necessary to continue electroCore's business,
sales and marketing and product development plans, the
uncertainties inherent in the development of new products or
technologies, the ability to successfully commercialize gammaCore™,
competition in the industry in which electroCore operates and
general market conditions. All forward-looking statements are made
as of the date of this press release, and electroCore undertakes no
obligation to update forward-looking statements or to update the
reasons why actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should refer to all information set forth in this document and
should also refer to the disclosure of risk factors set forth in
the reports and other documents electroCore files with the SEC,
available at www.sec.gov.Contact:ECOR Investor
Relations(973) 302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Apr 2024 to May 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From May 2023 to May 2024